Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Arbutus Biopharma Corp. buy melinda

Start price
€1.73
03.06.19 / 50%
Target price
€2.35
20.06.19
Performance (%)
36.98%
End price
€2.37
20.06.19
Summary
This prediction ended on 20.06.19 with a price of €2.37. With a performance of 36.98% the BUY prediction by melinda was a big success. melinda has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Arbutus Biopharma Corp. -1.417% -1.417% 6.102% 2.037%
iShares Core DAX® -0.922% -1.078% 12.165% 16.796%
iShares Nasdaq 100 0.371% -0.556% 38.622% 49.370%
iShares Nikkei 225® 2.224% -2.825% 19.015% 4.643%
iShares S&P 500 -0.026% -0.788% 28.485% 42.479%

According to melinda what are the pros and cons of Arbutus Biopharma Corp. for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Cons

Comments by melinda for this prediction

In the thread Arbutus Biopharma Corp. diskutieren
Prediction Buy
Perf. (%) 36.98%
Target price 2.345
Change
Ends at 20.06.19

Secteur Produits pharmaceutiques Agenda 15/08 | 06:00 Publication de résultats

Logo Arbutus Biopharma Corp.
Arbutus Biopharma Corp. est une société biopharmaceutique canadienne. Société se consacrant à la découverte, au développement et à la commercialisation d'un médicament remède pour les patients atteints d'hépatite B chronique, une maladie du foie causée par le virus de l'épépatite B (VHB). La Société de développement de médicaments candidats à l'action multiple multiple for a general treatment for guérir le VHB. En plus de son portefeuille de VHB, Société octroyée à l'industrie des licences de technologies de nanoparticules lipidiques (PNP). Cette technologie représente une technologie dans le développement thérapeutique de l'interférence ARN (ARNi), qui permet plusieurs essais cliniques et administré à des sujets humains.


Nombre d'employés

: 130 personnes.

Prediction Buy
Perf. (%) 36.98%
Target price 2.345
Change
Ends at 20.06.19

(Zielkurs erreicht)

Stopped prediction by melinda for Arbutus Biopharma Corp.

buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.20
24.12.23
-
24.12.24
1.36%
06.01.24

Could be worthwhile Investment >10% per year
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.03
08.07.23
-
08.07.24
-18.91%
26.11.23

Could be worthwhile Investment >10% per year
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€2.08
20.05.20
€4.50
04.11.21
56.99%
05.11.21

Could be worthwhile Investment >10% per year
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€3.14
06.01.20
-
20.05.20
-33.64%
20.05.20

Could be worthwhile Investment >10% per year
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€4.19
16.10.18
€6.31
02.11.18
13.55%
02.11.18

Could be worthwhile Investment >10% per year
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€6.55
21.10.17
€7.50
27.12.17
-26.72%
27.12.17

Could be worthwhile Investment >10% per year
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€5.91
21.10.17
€6.77
27.12.17
-26.72%
27.12.17

Could be worthwhile Investment >10% per year